Vaxon Biotech – Product Pipeline Review – H2 2011

Vaxon Biotech - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Vaxon Biotech - Product Pipeline Review - H2 2011” provides data on the Vaxon Biotech’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vaxon Biotech’s corporate website, SEC filings, investor presentations and featured press releases, both from Vaxon Biotech and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• Vaxon Biotech - Brief Vaxon Biotech overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of Vaxon Biotech human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Vaxon Biotech with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the Vaxon Biotech’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate Vaxon Biotech’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of Vaxon Biotech in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the Vaxon Biotech’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with Vaxon Biotech.
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of Vaxon Biotech and identify potential opportunities in those areas.

Contents

Vaxon Biotech Snapshot
Vaxon Biotech Overview
Key Information
Key Facts
Vaxon Biotech – Research and Development Overview
Key Therapeutic Areas
Vaxon Biotech – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vaxon Biotech – Pipeline Products Glance
Vaxon Biotech Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Vaxon Biotech – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vaxon Biotech – Drug Profiles
Vbx-016
  Product Description
  Mechanism of Action
  R&D Progress
Vbx-026
  Product Description
  Mechanism of Action
  R&D Progress
Vx-001
  Product Description
  Mechanism of Action
  R&D Progress
Vx-006
  Product Description
  Mechanism of Action
  R&D Progress
Vaxon Biotech – Pipeline Analysis
Vaxon Biotech – Pipeline Products by Therapeutic Class
Vaxon Biotech – Pipeline Products by Route of Administration
Vaxon Biotech – Pipeline Products by Molecule Type
Vaxon Biotech - Dormant Projects
Vaxon Biotech – Locations And Subsidiaries
Head Office
Company's Recent Developments
Vaxon Biotech, Recent Developments
May 19, 2010: Vaxon Biotech Successfully Completes Phase I/II Trial Of Vx-001 Cancer Vaccine
Nov 16, 2007: Vaxon Biotech Receives European Orphan Medicinal Product Designation For Vx-001
Mar 14, 2006: Vaxon-Biotech To Present Latest Clinical Data Of Its Vx-001 Cancer Vaccine At The AACR 97th Annual Meeting
Apr 11, 2008: Vaxon-Biotech To Present Latest Clinical And Immunological Data Of Its Vx-001 Cancer Vaccine At The AACR 99th Annual Meeting
Jun 03, 2007: Vaxon-Biotech Presents Preliminary Results From Vx-001 Vaccine Clinical Trial On Lung Cancer
Jul 02, 2007: Vaxon Biotech Publishes Encouraging Results In The Journal of Clinical Oncology For The Treatment Of Non-small Cell Lung Cancer With Vx-001.
Financial Deals Landscape
Vaxon Biotech, Deals Summary
Vaxon Biotech, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Vaxon Biotech Enters Into Co-Development Agreement With Institut Pasteur
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Vaxon Biotech, Key Information
Vaxon Biotech, Key Facts
Vaxon Biotech – Pipeline by Therapy Area and Indication, H2 2011
Vaxon Biotech – Pipeline by Stage of Development, H2 2011
Vaxon Biotech – Monotherapy Products in Pipeline, H2 2011
Vaxon Biotech - Phase II, H2 2011
Vaxon Biotech – Pre-Clinical, H2 2011
Vaxon Biotech – Discovery, H2 2011
Vaxon Biotech - Pipeline By Therapeutic Class, H2 2011
Vaxon Biotech – Pipeline By Route of Administration, H2 2011
Vaxon Biotech – Pipeline By Molecule Type, H2 2011
Vaxon Biotech - Dormant Developmental Projects, 2010
Vaxon Biotech, Deals Summary
Vaxon Biotech Enters Into Co-Development Agreement With Institut Pasteur

LIST OF FIGURES

Vaxon Biotech – Pipeline by Therapy Area and Indication, H2 2011
Vaxon Biotech – Pipeline by Stage of Development, H2 2011
Vaxon Biotech – Monotherapy Products in Pipeline, H2 2011
Vaxon Biotech – Pipeline By Therapeutic Class, H2 2011
Vaxon Biotech – Pipeline By Molecule Type, H2 2011 Skip to top